TARGET AUDIENCE
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of follicular lymphoma (FL).

OVERVIEW OF ACTIVITY
FL is an indolent form of non-Hodgkin lymphoma that can vary significantly in its clinical presentation. Because of this variation, no single standard approach to the initial management of FL has been established, and available options range from watchful waiting, radiation therapy or rituximab monotherapy to various combinations of chemoimmunotherapy. Recent data sets and corresponding FDA actions have led to the emergence of new therapeutic targets and regimens, thereby altering management algorithms. In order to offer patients the best possible care, including the option of clinical trial participation, the practicing medical oncologist must be well informed of these advances.

This program features a discussion with 2 leading hematology-oncology investigators. By providing information on the latest clinical developments in the context of expert perspectives, this activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of evidence-based therapeutic strategies, which in turn facilitates the optimal care of patients with FL.

LEARNING OBJECTIVES

• Evaluate published research data, recent FDA approvals and clinical investigator perspectives when designing an optimal therapeutic approach for patients with newly diagnosed follicular lymphoma (FL) requiring active therapy.
• Identify patient- and disease-specific factors that may portend poor response to initial chemoimmunotherapy, and consider this information in treatment decision-making for individuals with previously untreated FL.
• Appreciate the recent approval of rituximab/lenalidomide for the management of relapsed/refractory (R/R) FL and available Phase III data investigating its use as front-line therapy, and optimally incorporate this novel therapeutic approach into current treatment algorithms.
• Recall published research data in the best-practice selection, sequencing or combining of available therapeutic agents in the nonresearch care of patients with R/R FL.
• Compare and contrast the efficacy of the commercially available PI3K inhibitors idelalisib, copanlisib and duvelisib in the treatment of R/R FL to determine the appropriate role of each in clinical practice.
• Develop practical strategies to prevent, recognize and ameliorate the toxicities associated with therapies routinely used for patients with FL.
• Identify ongoing clinical trials evaluating innovative approaches for FL, and inform appropriately selected patients about these options for treatment.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

HOW TO USE THESE CME ACTIVITIES
Audio Program: This CME activity consists of an audio component.
CNE credit is no longer available for this issue

Video Program: This CME activity consists of a video component.
CNE credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Carla Casulo, MD
Associate Professor of Medicine
Division of Hematology/Oncology
Director, Hematology/Oncology Fellowship Program
University of Rochester
James P Wilmot Cancer Institute
New York, New York

No financial interests or affiliations to disclose.

John P Leonard, MD
Richard T Silver Distinguished Professor of Hematology and Medical Oncology
Senior Associate Dean for Innovation and Initiatives
Executive Vice Chair, Joan and Sanford I Weill Department of Medicine
Weill Cornell Medicine
New York, New York

Consulting Agreements: ADC Therapeutics SA, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Epizyme, Genmab, Karyopharm Therapeutics, Kite, A Gilead Company, MEI Pharma Inc, Miltenyi Biotec, Regeneron Pharmaceuticals Inc, Sutro Biopharma; Contracted Research: Celgene Corporation, Epizyme, Janssen Biotech Inc.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company and Genentech, a member of the Roche Group.

Release date: August 2020
Expiration date: August 2021